8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Sep 19, 2018)

Filed September 19, 2018For Securities:ABT

Summary

Abbott Laboratories (ABT) announced on September 18, 2018, through a Form 8-K filing, that its wholly-owned subsidiary, Abbott Ireland Financing DAC, plans to offer senior unsecured notes. This offering is being made in reliance on an exemption from registration under the Securities Act of 1933. Abbott Laboratories will provide a full and irrevocable guarantee for these notes on a senior unsecured basis. The primary purpose of this debt offering is to refinance existing debt. Specifically, Abbott intends to use the net proceeds to pay down portions or all of its outstanding 2.00% Notes due 2020, 4.125% Notes due 2020, 3.25% Notes due 2023, 3.4% Notes due 2023, and 3.75% Notes due 2026. This strategic move suggests a focus on optimizing the company's capital structure and potentially lowering its overall borrowing costs.

Key Highlights

  • 1Abbott Ireland Financing DAC, a subsidiary, intends to offer senior unsecured notes.
  • 2The offering is exempt from registration under the Securities Act of 1933.
  • 3Abbott Laboratories will fully and irrevocably guarantee the notes.
  • 4Proceeds will be used to refinance existing debt, including 2.00% and 4.125% notes due 2020, and 3.25%, 3.4%, and 3.75% notes due 2023 and 2026.
  • 5The announcement signals proactive debt management and capital structure optimization.
  • 6The notes are not registered and cannot be offered or sold in the US to US persons without registration or exemption.

Frequently Asked Questions

The main purpose of the new debt offering by Abbott Ireland Financing DAC is to refinance all or portions of Abbott Laboratories' outstanding senior unsecured notes due in 2020, 2023, and 2026. This aims to optimize the company's debt profile and potentially reduce borrowing costs.

Yes, Abbott Laboratories will fully and irrevocably guarantee the senior unsecured notes on a senior unsecured basis, meaning the parent company is directly liable for the debt.

The notes are being offered in an exempt offering and have not been registered under the Securities Act of 1933. They may not be offered or sold in the United States or to U.S. persons absent registration or an exemption from registration.

No, this specific 8-K filing (Item 7.01) is for Regulation FD Disclosure and relates solely to the planned offering of senior unsecured notes and the intended use of proceeds for debt refinancing. It does not contain updates on financial performance or new business developments.